A61K 2039/5154
Antigen presenting cells [apcs]
Official title: {Antigen presenting cells [APCs], e.g. dendritic cells or macrophages}
A61K2039/5154 (Antigen presenting cells [apcs]) appears on 505 US grants and 808 published applications in this corpus.
Search patents in A61K- Granted patents
- 505
- Published applications
- 808
- Assignees
- 366
- Inventors
- 1,219
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 3 | 0 |
| 1998 | 6 | 0 |
| 1999 | 10 | 0 |
| 2000 | 7 | 0 |
| 2001 | 11 | 2 |
| 2002 | 13 | 39 |
| 2003 | 14 | 32 |
| 2004 | 13 | 25 |
| 2005 | 19 | 36 |
| 2006 | 9 | 29 |
| 2007 | 9 | 21 |
| 2008 | 13 | 16 |
| 2009 | 16 | 25 |
| 2010 | 15 | 21 |
| 2011 | 17 | 21 |
| 2012 | 20 | 35 |
| 2013 | 7 | 11 |
| 2014 | 15 | 18 |
| 2015 | 14 | 33 |
| 2016 | 20 | 27 |
| 2017 | 15 | 32 |
| 2018 | 21 | 42 |
| 2019 | 31 | 43 |
| 2020 | 24 | 42 |
| 2021 | 37 | 56 |
| 2022 | 32 | 57 |
| 2023 | 23 | 56 |
| 2024 | 33 | 30 |
| 2025 | 18 | 28 |
| 2026 | 19 | 31 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method of treatment of cancer or tumour29 Sep 2026US 12,746,272 B2
- FOXM1-derived peptide, and vaccine including same29 Sep 2026US 12,747,265 B2Oncotherapy Science, Inc.
- Method for stimulating T cell response against lymphoblastic leukemia with leukemia tumor specific antigens1 Sep 2026US 12,721,812 B2Universite de Montreal
- Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)25 Aug 2026US 12,714,745 B2Baylor Research Institute
- Prostate neoantigens and their uses28 Jul 2026US 12,692,513 B2Janssen Biotech, Inc.
- Rcn1-derived teipp neoantigens and uses thereof24 Sep 2026US 2026/0285905 A1
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy17 Sep 2026US 2026/0272985 A1Iovance Biotherapeutics, Inc.
- Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy17 Sep 2026US 2026/0272986 A1Iovance Biotherapeutics, Inc.
- Antigen-specific physiologic dendritic cells for vaccination17 Sep 2026US 2026/0273045 A1Emory University
- Disruption of telocyte activity10 Sep 2026US 2026/0263514 A1
Most cited
By later US patents
- Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides190US 5,679,647 AThe Regents of the University of California · 1997
- Tolerogenic synthetic nanocarriers for inducing regulatory B cells129US 8,652,487 B2Selecta Biosciences, Inc. · 2014
- Non-linear amplitude dielectrophoresis waveform for cell fusion117US 6,916,656 B2Cyto Pulse Sciences, Inc. · 2005
- Method for treating allergic lung disease110US 5,849,719 AThe Regents of the University of California · 1998
- Anti-CD40 monoclonal antibodies capable of blocking B-cell activation109US 5,677,165 AChiron Corporation · 1997